Idera Pharmaceuticals, Inc. (IDRA)

NASDAQ: IDRA · IEX Real-Time Price · USD
0.332
-0.038 (-10.39%)
At close: Nov 29, 2022 3:57 PM
0.335
+0.003 (0.78%)
After-hours: Nov 29, 2022 4:34 PM EST
-10.39%
Market Cap 23.12M
Revenue (ttm) n/a
Net Income (ttm) -16.22M
Shares Out 53.29M
EPS (ttm) -0.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 84,995
Open 0.356
Previous Close 0.371
Day's Range 0.33 - 0.37
52-Week Range 0.3 - 0.95
Beta 1.49
Analysts Sell
Price Target n/a
Earnings Date Nov 14, 2022

About IDRA

Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 198... [Read more]

Industry Biotechnology
IPO Date Jan 24, 1996
CEO Vincent Milano
Employees 13
Stock Exchange NASDAQ
Ticker Symbol IDRA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

No stock price forecast available yet.

Price Target
n/a
Analyst Consensus: Sell
Stock Forecasts

News

Idera Pharmaceuticals Acquires Aceragen

Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024

2 months ago - GlobeNewsWire

Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results

EXTON, Pa., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the secon...

3 months ago - GlobeNewsWire

Why Are Idera Pharmaceuticals Shares Soaring Today

Idera Pharmaceuticals Inc (NASDAQ: IDRA) shared positive interim results from its investigator-sponsored Phase 2 trial, INTRIM 1, involving tilsotolimod, Idera's synthetic Toll-like receptor 9 agonist. ...

6 months ago - Benzinga

Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC

– Enrollment Stopped Early for Efficacy – – Enrollment Stopped Early for Efficacy –

6 months ago - GlobeNewsWire

Idera Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

EXTON, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the first ...

6 months ago - GlobeNewsWire

Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

EXTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the four...

7 months ago - GlobeNewsWire

Idera Pharmaceuticals Announces Tilsotolimod Updates

EXTON, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” and “our”) (Nasdaq: IDRA) today announced clinical updates regarding tilsotolimod, its synt...

11 months ago - GlobeNewsWire

Idera Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

EXTON, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the third...

1 year ago - GlobeNewsWire

Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

EXTON, Pa., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June...

1 year ago - GlobeNewsWire

Why Idera Shares Are Skyrocketing Today

Idera Pharmaceuticals Inc (NASDAQ:IDRA) shares are trading higher by 43% at $1.60 after it was disclosed in a Form 4 filing the company COO Daniel Soland purchased 50,000 shares of the company stock at ...

1 year ago - Benzinga

Idera Will Not Continue Tilsotolimod/Ipilimumab Combo Melanoma Trial Into OS Primary Endpoint

Idera Pharmaceuticals Inc (NASDAQ: IDRA) has decided not to continue the ILLUMINATE-301 Phase 3 trial evaluating tilsotolimod in melanoma to its overall survival (OS) primary endpoint. The trial assesse...

1 year ago - Benzinga

Idera Pharmaceuticals Announces Corporate Updates

EXTON, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today announced that it will not continue ILLUMINATE-301, the Company's trial of tilsot...

1 year ago - GlobeNewsWire

Idera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

EXTON, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended Marc...

1 year ago - GlobeNewsWire

Tomslist: The 5 Weirdest Penny Stock Stories of the Week

Even the best penny stocks have their dog days. Here's a celebration of this week's weirdest plays: SNES, IDRA, SOS, TSNPD and HLLPF.

Other symbols: SNESSOS
1 year ago - InvestorPlace

Why Idera Pharmaceuticals Stock Is Crashing Today

The company's experimental cancer drug flopped in a late-stage study.

1 year ago - The Motley Fool

Idera Pharmaceuticals stock plunges after disappointing trial results, prompting analyst downgrade

Shares of Idera Pharmaceuticals Inc. plummeted 63.3% in active trading to pace all premarket decliners, after the immunotherapy company said the ILLUMINATE-301 pivotal registration trial of its treatmen...

1 year ago - Market Watch

Why Idera Pharmaceuticals Shares Dropped 62% Lower Today

Shares of Idera Pharmaceuticals Inc. (NASDAQ: IDRA) plunged more than 62% in the extended session Thursday after the biopharmaceutical company said its lead drug candidate Tilsotolimod failed to meet th...

1 year ago - Benzinga

Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractor...

– Objective Response Rate Endpoint Not Met – – Objective Response Rate Endpoint Not Met –

1 year ago - GlobeNewsWire

Are Options Traders Betting on a Big Move in Idera Pharmaceuticals (IDRA) Stock?

Investors need to pay close attention to Idera Pharmaceuticals (IDRA) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

ILLUMINATE-301 Continues on Track for Data Later this Month ILLUMINATE-301 Continues on Track for Data Later this Month

1 year ago - GlobeNewsWire

Idera Pharmaceuticals to Present at Upcoming Conferences

EXTON, Pa., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will provide a company outlook for 2021 at upcoming conferences.

1 year ago - GlobeNewsWire

Idera Pharmaceuticals (IDRA) in Focus: Stock Moves 9.4% Higher

Idera Pharmaceuticals (IDRA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 Million

EXTON, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the closing of a second tranche under its April 7, 2020, securities purchase agreement (the “Purc...

1 year ago - GlobeNewsWire

Idera Pharmaceuticals Announces Dan Soland to Join as Chief Operating Officer

– COO Role is Key to Preparedness for NDA Filing and Commercial Launch – – Clayton Fletcher , Head of Business Development & Strategic Planning , to Retire –

2 years ago - GlobeNewsWire

Idera Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update

ILLUMINATE-301 Continues on Track and Beyond Melanoma Strategy Advances ILLUMINATE-301 Continues on Track and Beyond Melanoma Strategy Advances

2 years ago - GlobeNewsWire